Literature DB >> 7506712

Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. Evidence for protein kinase C-mediated suppression of the cholinergic response.

P A Craven1, R K Studer, F R DeRubertis.   

Abstract

Nitric oxide (NO)-dependent cyclic guanosine monophosphate (cGMP) generation was examined in glomeruli isolated from 1-2-wk and 2-mo streptozotocin diabetic (D) and control (C) rats. After 1-2 wk of diabetes, ex vivo basal cGMP generation and cGMP responses to carbamylcholine (CCh) were significantly suppressed in glomeruli from D compared with those from C, whereas cGMP responses to the calcium ionophore A23187 and nitroprusside (NP) did not differ in glomeruli from D vs. those from C. After 2 mo, glomeruli from D did not respond to CCh, and responses to A23187 and NP were suppressed compared with those from C. Differences in basal, CCh, and A23187-responsive cGMP between D and C were abolished by the NO synthetase inhibitor NG-monomethyl-L-arginine. Soluble glomerular guanylate cyclase prepared from either D or C responded indistinguishably to NP, suggesting a role for NO quenching in the suppression of cGMP in intact glomeruli from D. Compared with those from C, glomeruli isolated from D demonstrated increased generation of thromboxane A2 (TXA2) and activation of protein kinase C (PKC). Both the TXA2/endoperoxide receptor antagonist Bay U3405 and inhibitors of PKC activity restored a cGMP response to CCh in glomeruli from D. Conversely, in glomeruli from C, the TXA2/endoperoxide analogue U46619 activated PKC and suppressed the cGMP response to CCh. Both of those actions were blocked by inhibitors of PKC. The results indicate a progressive impairment of NO-dependent cGMP generation in glomeruli from D which may be mediated in part by TXA2 and activation of PKC. This impairment may participate in glomerular injury in diabetes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7506712      PMCID: PMC293768          DOI: 10.1172/JCI116961

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

1.  Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C.

Authors:  B Tesfamariam; M L Brown; R A Cohen
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

2.  Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy.

Authors:  K Hora; H Oguchi; T Furukawa; K Hora; S Tokunaga
Journal:  Nephron       Date:  1990       Impact factor: 2.847

3.  Effects of amino acid infusion on renal hemodynamics. Role of endothelium-derived relaxing factor.

Authors:  J P Tolins; L Raij
Journal:  Hypertension       Date:  1991-06       Impact factor: 10.190

4.  Glomerular hemodynamics in experimental diabetes mellitus.

Authors:  T H Hostetter; J L Troy; B M Brenner
Journal:  Kidney Int       Date:  1981-03       Impact factor: 10.612

5.  The effects of endothelin-1 and NG-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus.

Authors:  R J Kiff; S M Gardiner; A M Compton; T Bennett
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

6.  Thromboxane stimulates synthesis of extracellular matrix proteins in vitro.

Authors:  L A Bruggeman; E A Horigan; S Horikoshi; P E Ray; P E Klotman
Journal:  Am J Physiol       Date:  1991-09

7.  Effect of arginine depletion on glomerular and tubular kidney function: studies in isolated perfused rat kidneys.

Authors:  J Radermacher; B Klanke; S Kastner; G Haake; H J Schurek; H F Stolte; J C Frölich
Journal:  Am J Physiol       Date:  1991-11

8.  Contribution of platelet thromboxane production to enhanced urinary excretion and glomerular production of thromboxane and to the pathogenesis of albuminuria in the streptozotocin-diabetic rat.

Authors:  F R DeRubertis; P A Craven
Journal:  Metabolism       Date:  1992-01       Impact factor: 8.694

9.  Inactivation of endothelial derived relaxing factor by oxidized lipoproteins.

Authors:  J H Chin; S Azhar; B B Hoffman
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

10.  Role of prostaglandins and endothelium-derived relaxing factor on the renal response to acetylcholine.

Authors:  M G Salom; V Lahera; J C Romero
Journal:  Am J Physiol       Date:  1991-01
View more
  17 in total

Review 1.  Diabetic periodontitis: a model for activated innate immunity and impaired resolution of inflammation.

Authors:  Hamdy Nassar; Alpdogan Kantarci; Thomas E van Dyke
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

2.  Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; K Bridget Brosnihan; Javad Habibi; Roger D Tilmon; James R Sowers; Carlos M Ferrario
Journal:  Am J Nephrol       Date:  2010-11-02       Impact factor: 3.754

Review 3.  Molecular insights and therapeutic targets for diabetic endothelial dysfunction.

Authors:  Jian Xu; Ming-Hui Zou
Journal:  Circulation       Date:  2009-09-29       Impact factor: 29.690

Review 4.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.

Authors:  H C Ringvold; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-07-18

5.  Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats.

Authors:  Yoshihiro Kuno; Masayuki Iyoda; Takanori Shibata; Yuki Hirai; Tadao Akizawa
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

Review 6.  Reno-protective effects of Phosphodiesterase 5 inhibitors.

Authors:  Enis Rauf Coskuner; Burak Ozkan
Journal:  Clin Exp Nephrol       Date:  2021-03-22       Impact factor: 2.801

7.  Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice.

Authors:  Yukiko Kanetsuna; Keiko Takahashi; Michio Nagata; Maureen A Gannon; Matthew D Breyer; Raymond C Harris; Takamune Takahashi
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

8.  Modulation of basal nitric oxide-dependent cyclic-GMP production by ambient glucose, myo-inositol, and protein kinase C in SH-SY5Y human neuroblastoma cells.

Authors:  H Shindo; T P Thomas; D D Larkin; A K Karihaloo; H Inada; T Onaya; M J Stevens; D A Greene
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

Review 9.  Phosphodiesterase type 5 inhibitors and kidney disease.

Authors:  Baris Afsar; Alberto Ortiz; Adrian Covic; Abduzhappar Gaipov; Tarik Esen; David Goldsmith; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-08-05       Impact factor: 2.370

Review 10.  Role of nitric oxide in insulin-dependent diabetes mellitus-related vascular complications.

Authors:  O Traub; R Van Bibber
Journal:  West J Med       Date:  1995-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.